Thanks Defater for let us know about this sad news.
As a junior member of this forum, I do appreciate the insightful ideas shared by a number of experts/contributors, and Miner is one of these kind people.
Condolences to his family and friends.
Printable View
Thanks Defater for let us know about this sad news.
As a junior member of this forum, I do appreciate the insightful ideas shared by a number of experts/contributors, and Miner is one of these kind people.
Condolences to his family and friends.
Upward movement, with $0.50 being breached, not aware of any news aside from results announcement next Thursday.
https://www.nzx.com/announcements/402943
FINANCIAL RESULTS FOR THE HALF YEAR TO 30 SEPTEMBER 2022
PACIFIC EDGE INVESTMENT FOR GROWTH DELIVERS EARLY RESULTS
HIGHLIGHTS
• Operating revenue from test sales increases 62% to $8.7 million when compared to the same period of the prior year (1H22); total revenue increases 102% to $13.6 million when compared with 1H22, with increases from commercial test volume growth boosted by foreign exchange gains
• Total laboratory throughput rises 34% to 14,917 in line with analyst expectations, lifted by a 35% increase in commercial test volumes to 12,422, with growth led by the US market
• Investments driving Cxbladder adoption and lifting US clinician engagement; staff numbers increase from 86 at the end of March 2022 to 100 full-time-equivalents (FTE) at 30 September 2022
• Kaiser Permanente using Cxbladder Triage at 11 sites, two of which are in the Top 20 sites by volume during 1H23
• Net losses after tax increased to $10.6 million, from $9.0 million in 1H22 as Pacific Edge continues to invest for growth
• Cash, cash equivalents and short-term deposits of $93.5 million as at 30 September 2022, down from $105.4 million at 31 March 2022, provides strong foundation for continued investment
• Optimistic outlook tempered by proposed LCD from Novitas and the potential to affect Medicare reimbursement.
Out of a morbid fascination of this company I looked at the Balance Sheet
Accumulated Losses rolled over the $200m mark
Another milestone met?
I like to keep an eye on NZ test sales. Insignificant in the overall scheme of things but given the tests are apparently in the clinical pathway here, I'd have thought a reasonable yardstick for future US growth. NZ test sales down 30%. All a bit queer.
100 sales staff on the ground in the US eh, becoming quite an operation. So much resting on the CMS review...
and on the KP EMR integration which in itself will be a big step forwards. Results preso about to start for those interested
I would like to know where you saw that because all I can find is
”In the Asia Pacific, where test numbers are dominated by the relatively mature New Zealand market, total laboratory throughput volumes were flat versus the same period a year ago at 2,148 tests. Commercial test volumes increased 5% to 1,800 tests.”
Hi Brain, sales by region is broken down in the notes to Financial Accounts. Cheers
I am particularly missing Miner's presence today.......
More good news
Price Sensitive as well
http://nzx-prod-s7fsd7f98s.s3-websit...937/385487.pdf